GENE ONLINE|News &
Opinion
Blog

2021-12-03| ChinaIPO

BeiGene launches IPO on Shanghai’s STAR market to raise $3B

by Sahana Shankar
Share To
BeiGene Ltd announces the third round of its initial public offering (IPO) on the STAR market of Shanghai Stock Exchange to raise US $3.5 billion. The global biotech company, based in Beijing, China offers around 115 million ordinary shares, representing 8.62% of its total outstanding shares. 

GO Prime with only $1.49 now

LATEST
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
Rice University Engineers Develop Miniature Brain Stimulator for Safer and Less-invasive Neuromodulation
2024-04-17
Breakthrough Screening Platform to Assess SARS-CoV-2 Mutations and Potential Treatments
2024-04-16
Join Us for the SABPA OC/LA 16th Annual Biomedical Forum!
2024-04-16
Sequencing Revolution Spotlights the Titans of NGS Innovation
2024-04-16
Oncology’s New Drugs on the Horizon (II): Radiotherapy, Radioligands & Other Therapeutic Agents
2024-04-12
EVENT
2024-04-20
16th SABPA OC/LA Annual Biomedical Forum
The Beckman Center, 100 Academy, Irvine, CA, 92617
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top